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Abstract: Asenapine is a new atypical antipsychotic agent currently under development for 
the treatment of schizophrenia and bipolar disorder. It has high affinity for various receptors 
including antagonism at 5HT2A, 5HT2B, 5HT2C, 5HT6 and 5HT7 serotonergic receptor subtypes, 
α1A, α2A, α2B and α2C adrenergic and D3 and D4 dopaminergic receptors. As with other atypicals, 
asenapine exhibits a high 5HT2A:D2 affinity ratio. Although similar to clozapine in its multi-
target profile, it shows no appreciable affinity for muscarinic receptors. Asenapine has shown 
efficacy in alleviating both positive and negative symptoms of schizophrenia compared with 
placebo. Although promising, further studies are required in order to determine whether it has 
advantages over placebo and other antipsychotics in alleviating cognitive impairment associated 
with schizophrenia. It has also shown long-term efficacy comparable with olanzapine in bipolar 
I disorder. Asenapine is generally well tolerated and appears to be metabolically neutral. It has 
low propensity to cause weight gain and prolactin elevation. There were no concerns in the 
studies about its effects on the cardiovascular system and QTc prolongation. The incidence of 
extrapyramidal symptoms with asenapine however has been found to be higher than that with 
olanzapine. It may be a useful alternative to aripiprazole in schizophrenia and bipolar disorder 
in patients who are at high risk of metabolic abnormalities.
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Introduction
Schizophrenia
The symptoms of schizophrenia are thought to result from the dysfunction of several 
neurotransmitters mainly dopamine1 and serotonin2 although noradrenaline, acetyl-
choline and glutamate have also been implicated.3 The multidimensional facet of the 
disorder means that life-long therapeutic intervention with psychotropic agents and 
principally antipsychotics is often warranted. Although the specific mechanism of action 
of antipsychotics is still not fully understood, the antagonism of dopamine transmission 
is likely to play a major role. The dopamine system affects the mesolimbic, striatal and 
cortical areas of the brain. Neurones in the midbrain release dopamine which interacts 
with dopamine receptors. Antipsychotics block dopaminergic transmission by binding 
to these dopamine receptors, in particular D2 receptors, the affinity for which correlates 
with the clinical dose in many cases.4
The history of antipsychotic drug development has been haphazard. In 1952, the 
accidental use of chlorpromazine revolutionized the treatment of schizophrenia. In the 
following years, several other first-generation or typical antipsychotics were launched 
and although this group of antipsychotic agents were effective in managing the positive Neuropsychiatric Disease and Treatment 2009:5 484
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symptoms of schizophrenia, they demonstrated relatively 
poor efficacy for negative symptoms and associated cognitive 
impairment. Typical antipsychotics have also been associated 
with severe and devastating extrapyramidal symptoms (EPS)5 
and tardive dyskinesia,6 thus limiting their long-term use. In 
addition, adverse effects relating to elevation in serum prolactin7 
also made their use problematic. It is thought that the blockade 
of dopamine D2 receptors is responsible for the antipsychotic-
induced movement disorders and rise in prolactin.4
The introduction of second generation, or atypical 
antipsychotics, over the last 20 years has contributed 
considerably to the advancement in the treatment of schizo-
phrenia, both in terms of scope of efficacy and more favorable 
tolerability in some respects. Atypical antipsychotics have 
demonstrated clinical effectiveness comparable to that with 
typical antipsychotics with regards to positive symptoms8 and 
are argued to be more effective in the management of negative 
symptoms9,10 and cognitive impairment.11,12 Moreover, they 
are associated with a significantly lower incidence of EPS.13 
As a result, atypicals quickly replaced the older typical 
antipsychotics and for many years they were considered the 
treatment of choice in the management of schizophrenia.14
The atypical antipsychotic clozapine which was actually 
synthesized shortly after chlorpromazine in the 1950s, has 
a unique pharmacological profile in view of its affinity for 
a diverse range of receptors. These include D1, D2 and D4 
dopaminergic, α1 and α2 adrenergic, H1 histaminergic and 
muscarinic receptors as well as various serotonin receptor 
subtypes.15 Consequently, clozapine has unique properties in 
the prevention of suicide16 and treatment-refractory schizo-
phrenia (TRS),17 although there has been some suggestion 
that other antipsychotics such as olanzapine may also be 
effective in TRS at higher than typically prescribed doses.18 
In addition to clozapine’s superior efficacy profile, it has a 
more favorable motor system side effect profile, with minimal 
risk of causing EPS or tardive dyskinesia.19 Its use however 
is somewhat limited by its potential to cause neutropenia and 
agranulocytosis,20 of possibly fatal consequence if it were not 
for the strict haematological monitoring requirements which 
are obligatory with the use of clozapine.
Several hypotheses have been put forward to explain the 
differences in clinical and adverse effect profiles between 
typical and atypical antipsychotic drugs. It has been 
suggested that atypical drugs have a stronger 5HT2A receptor 
affinity compared with that for the D2 receptor21 leading to 
their lower propensity to cause EPS and prolactin elevation. 
This hypothesis, however, has been challenged with the 
suggestion that the “atypicality” of atypical agents is actually 
due to the fast dissociation from the D2 receptor, resulting in 
transient and easily reversible occupancy of this receptor.22 
In addition, the fact that atypicals have a moderate D2 receptor 
occupancy23 compared with typicals has also been proposed 
as an explanation for their different profiles.
However, despite atypicals having shown more favorable 
tolerability for movement disorders and prolactin-related 
adverse effects, other serious safety concerns have surfaced 
over the years with certain agents in this class. Metabolic24 
and cardiovascular disease25 including weight gain, increased 
plasma lipids, new onset diabetes, prolongation of QTc 
interval and sudden death are the most concerning adverse 
effects of atypical agents, which were once considered 
relatively safe.
In the last decade, drug development in the field 
of schizophrenia has slowed somewhat, with the only 
advancement having been the introduction of the dopamine 
partial agonist, aripiprazole. Dopamine partial agonists 
are thought to exert their effects by acting as dopamine 
antagonists in the mesolimbic system where there is a high 
concentration of dopamine, however, in the mesocortical 
system where reduced dopamine activity is thought to 
produce negative symptoms and cognitive impairment, they 
act as dopamine agonists, thus the concept of dopamine 
system stabilization.26,27 Since the launch of aripiprazole in 
2004, no new antipsychotics have emerged on the market.
Bipolar disorder
The complexities of managing bipolar disorder are numerous. 
Firstly, the diagnostic criteria used for diagnosing bipolar 
disorder by psychiatrists in different parts of the world varies, 
resulting in a lack of clear distinction between schizophrenia 
and bipolar disorder thus influencing the management of 
the condition worldwide. Secondly, different treatments 
need to be considered separately for the specific manic, 
hypomanic, mixed and depressive episodes in addition to 
whether control of the acute state or maintenance of therapy is 
required. Furthermore, the pathogenesis and neurochemistry 
of bipolar disorder remains unclear, although serotonergic, 
noradrenergic and dopaminergic transmitter systems appear 
to be targeted during therapy.
For over 50 years, traditional mood stabilizers such as lithium 
have been the mainstay of therapy in bipolar disorder. However, 
increasingly atypical antipsychotics are also establishing them-
selves, with several agents having received regulatory approval 
for use in both bipolar depression and mania.
Of the atypicals, olanzapine28 and quetiapine29 have shown 
significantly greater efficacy than placebo in the treatment Neuropsychiatric Disease and Treatment 2009:5 485
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of bipolar depression. Both agents are known to antagonize 
5HT2A receptors as well as D2 receptor blockade. Their 
antagonistic effects on 5HT2A receptors, which are present 
on presynaptic dopamine neurons, are thought to lead to an 
increase in dopamine levels in the prefrontal cortex. It would 
appear therefore that a selective balance between dopamine 
and serotonin in specific regions of the brain is necessary in 
order to stabilize mood. In addition, quetiapine’s metabolite 
N-desalkylquetiapine, has been shown to be a potent nor-
adrenaline re-uptake inhibitor and partial 5HT1A agonist, 
also contributing to its antidepressant activity.30 Furthermore, 
olanzapine also exhibits potent antagonistic activity at α1 
adrenergic receptors leading to substantial increases in the 
firing neurons in the locus ceruleus with resulting increase 
in noradrenaline release in the prefrontal cortex.31
Atypicals are generally thought to owe their antimanic 
properties to their antagonism at dopamine receptors, 
although it is believed that antagonism at α1 adrenergic, H1 
histaminergic and serotonergic receptors may also play a role. 
However, unlike with bipolar depression, the importance of 
blocking 5HT2A serotonergic receptors in the treatment of 
mania is still unclear.32
Asenapine
Pharmacology and mode of action
Asenapine is novel pharmacological agent currently under 
clinical development for the treatment of schizophrenia and 
bipolar disorder. This new antipsychotic has high affinity for 
a number of receptors including antagonism at 5HT2A, 5HT2B, 
5HT2C, 5HT6 and 5HT7 serotonergic receptor subtypes, α1A, α2A, 
α2B and α2C adrenergic and D3 and D4 dopaminergic receptors. 
As with atypical antipsychotics, asenapine also exhibits an 
appreciable affinity for D2 receptors with a high 5HT2A: D2 
affinity ratio. Although similar to clozapine in its high affinity 
for a variety of different receptors, it has no appreciable affinity 
for muscarinic receptors, with the highest ratio of separation 
existing for its affinity for D2: M1, M2, M3 and M4 receptors.33
The multi-target nature of this new atypical antipsychotic 
agent has led to certain expectations for both its efficacy 
and tolerability. The higher affinity of asenapine for 5HT2A 
receptors relative to D2 receptors gives it its “atypicality” as 
it is an important mechanism thought to be responsible for 
enhanced efficacy of antipsychotics and reduced potential to 
cause EPS.34,35 In addition, antagonism at 5HT2A receptors, 
leading to an increase in dopamine activity in the prefrontal 
cortex, has also been suggested as a possible mechanism for 
alleviating negative symptoms2,35 and enhancing cognition36 in 
schizophrenia and other disorders. Findings from rat studies 
deduced that asenapine causes a dose-dependent increase in 
cortical37 and hippocampal dopamine37, noradrenaline38 and 
acetylcholine38 comparable to previous reports with clozapine 
and quetiapine. Similarly, the 5HT2C receptor may also have 
a similar role as 5HT2A and its antagonism has been linked to 
improvement in negative symptoms.39 Therefore, the combined 
antagonism at 5HT2A and 5HT2C which occurs with asenap-
ine may prove promising for the management of negative 
symptoms.
The resulting clinical effects of a high affinity for other 
serotonin receptor subtypes such as 5HT6 and 5HT7 are still 
unclear. Emerging evidence however suggests that 5HT6 
antagonism may afford benefits for cognition40 and that 5HT7 
antagonism may confer benefits for anxiety management and 
mood regulation as well as cognition.41 Such claims with 
asenapine however remain to be explored further.33 Similarly, 
activity at α-adrenergic receptors has also been suggested 
to improve negative and cognitive symptoms by antagonism 
of α2 receptors, whereas improvement in positive symptoms 
is via α1 receptor antagonism.42 Since asenapine appears to 
have relatively high affinity for adrenergic receptors, and 
more specifically α2 receptors43, it may potentially offer these 
therapeutic benefits.
Data from preclinical studies also suggests that 
antagonism at D3 receptors may help ameliorate negative and 
cognitive symptoms,44 although again the clinical evidence 
with asenapine for this is still lacking. Indeed, in animal 
models, asenapine did not improve cognition in rats, but 
rather, at doses greater than those required for antipsychotic 
activity, it impaired cognitive performance due to disturbance 
of motor function.45 This effect has also been observed with 
both olanzapine and risperidone. In contrast, in studies with 
monkeys, asenapine produced substantial improvement in 
executive functions which were maintained across a period of 
long-term dosing.46 Further studies in rat brain have indicated 
that chronic treatment with asenapine exerts regional and 
dose-dependent effects on inotropic glutamate receptors,47 
thus another potential mechanism for its effectiveness in 
schizophrenia.
Since olanzapine and clozapine’s high muscarinic receptor 
binding affinity is thought to be responsible for contributing 
to their anticholinergic adverse effects and potentially causing 
metabolic syndrome (via M3 antagonism),48 asenapine’s 
minimal antimuscarinic activity means that it may therefore 
be less likely to cause these effects.33 In the animal models, 
asenapine induced a marked increase in dopamine in the 
nucleus accumbens compared to the core region, sharing a 
similar profile to other atypical antipsychotics. In addition, Neuropsychiatric Disease and Treatment 2009:5 486
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results from microdialysis and electrophysiological techniques 
found that asenapine potentiates prefrontal dopaminergic 
as well as glutaminergic transmission, indicating a highly 
potent antipsychotic activity with very low propensity for 
EPS.49 Whether this receptor binding profile and related 
pharmacology of asenapine will actually translate into such 
clinical benefits in practice still remains to be ascertained 
by ongoing studies in the management of schizophrenia and 
bipolar disorder.
Pharmacokinetics
Results from separate phase I studies assessing the 
pharmacokinetic interactions between asenapine and several 
cytochrome P450 (CYP) modulators and the glucuronyl 
transferase (UGT) inhibitor valproate found that asenapine 
exposure was increased by fluvoxamine but was otherwise 
minimally affected. Asenapine was found to have a maximum 
plasma concentration occurring at 0.5 to 1.5 hours after oral 
administration and an elimination half life of approximately 
24 hours, following single dosing. In addition, there were 
no significant correlations between creatinine clearance 
and asenapine exposure in renal impairment. However, 
although mild or moderate hepatic impairment did not affect 
asenapine exposure, severe hepatic impairment increased 
exposure 7-fold. Furthermore, smoking was found not to 
affect exposure to asenapine therapy.50
Efficacy and safety studies 
in schizophrenia
In a 6-week, double-blind study investigating the efficacy and 
tolerability of asenapine in acute schizophrenia,51 patients 
were randomly assigned to receive twice daily doses of 
sublingual asenapine 5 mg, placebo or oral risperidone 3 mg. 
Results for the primary efficacy outcome measure, the Positive 
and Negative Syndrome Scale (PANSS) total score52 for the 
intention to treat population comprising 174 patients found 
mean changes at end point from baseline were –15.9 with 
asenapine, vs –5.3 with placebo (P  0.005); the change 
with risperidone (–10.9) compared with placebo however 
was non-significant. Asenapine produced significantly greater 
decreases in PANSS total scores compared with placebo from 
week 2 onward.51
Secondary efficacy measures included the PANSS 
positive subscale, which showed mean changes at endpoint 
from baseline of –5.5 for asenapine vs –2.5 for placebo 
(P = 0.01) and –5.1 for risperidone (P  0.05). Asenapine 
produced significant reductions in PANSS positive subscale 
scores from week 3 onward. PANSS negative score results 
showed mean changes at endpoint from baseline of –3.2 
for asenapine vs –0.6 for placebo (P = 0.01) and a non-
significant change of –1.05 with risperidone compared with 
placebo. Significant decreases in PANSS negative subscale 
scores were again seen with asenapine from week 3 onward. 
For Clinical Global Impression-Severity (CGI-S) scores,53 
both active treatments were associated with significantly 
greater decreases in CGI-S scores from week 4 onward. 
At endpoint, mean changes from baseline were –0.74 for 
asenapine and –0.75 for risperidone vs –0.28 for placebo 
(P  0.01 and P  0.005 respectively). Overall, the main 
efficacy findings from this study suggest that asenapine 
5 mg twice daily is superior to placebo in treating positive 
and negative symptoms of schizophrenia. Risperidone 3 mg 
twice daily, however, was superior to placebo in alleviating 
the positive symptoms but its effects on negative symptoms 
were non-significant compared with placebo,51 in contrast 
to previous studies showing significant improvements in 
negative symptoms with risperidone.10,54
In the same study,51 investigations into the safety 
and tolerability of asenapine found that 83% of patients 
assigned to the drug experienced at least 1 adverse event 
compared with 79% of patients assigned to placebo and 
90% assigned to risperidone. The most frequently reported 
adverse events in the asenapine group were insomnia (11%), 
somnolence (11%), nausea (11%) and anxiety (10%).51
The incidence of clinically significant weight gain with 
asenapine was equivalent to that seen with placebo, whereas 
the incidence with risperidone was higher, in accordance with 
previous reports. Similarly, asenapine had minimal effects 
on prolactin and metabolic parameters. The proportion 
of patients with normal baseline prolactin levels but with 
post-baseline levels of 2 times the laboratory upper limit of 
normal (ULN) were 9%, 2% and 79% for asenapine, placebo 
and risperidone groups respectively. Similarly, post-baseline 
fasting glucose levels 20% above ULN were observed 
in 14%, 12% and 20% of patients assigned asenapine, 
placebo and risperidone respectively. Moreover, mean 
changes from baseline in total cholesterol were –0.4, –1.7 
and +2.3 mmol/L and mean changes in fasting triglycerides 
were 0, –0.1 and 0 mmol/L for asenapine, placebo and 
risperidone groups respectively.51
Cardiovascular assessments found no clinically important 
differences between the groups with respect to blood 
pressure, heart rate and ECG changes.51
A further study examined the long-term safety of 
asenapine in patients with schizophrenia.55 The phase III, 
double-blind, 1-year-long trial included 1219 patients, Neuropsychiatric Disease and Treatment 2009:5 487
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randomly assigned (3:1 ratio) to asenapine 10 to 20 mg and 
olanzapine 20 to 40 mg a day. The 2 groups were comparable 
in terms of frequency of adverse events experienced (60% 
and 61% in asenapine and olanzapine groups respectively) 
and withdrawals due to serious adverse events (6.3% and 
6.8% respectively).55
In contrast, differences were apparent with regards 
to incidence of EPS (18% vs 8%), mean weight gain 
(1.6 kg vs 5.6 kg) and significant weight gain of 7% of 
original body weight (14.7% vs 36.1%) for asenapine and 
olanzapine groups respectively. Cardiovascular assessments 
found that the incidence of QTcF (Fridericia’s correction 
formula) 500 ms or prolongation 60 ms was 0% and 
0.3% for asenapine and olanzapine respectively. In addition, 
both groups showed small mean declines in prolactin levels 
and small mean changes were noted for fasting glucose, 
cholesterol and triglycerides.55
The effects of asenapine on cardiovascular parameters 
were compared with those for quetiapine and placebo in a 
16-day multicenter, randomized, double-blind, parallel-group 
study of 148 patients with schizophrenia or schizoaffective 
disorder.56 Patients were randomized to one of the 4 following 
groups: asenapine 5 mg twice daily for 10 days then 
asenapine 10 mg twice daily for 6 days; asenapine 15 mg 
twice daily for 10 days then asenapine 20 mg twice daily 
for 6 days; quetiapine 375 mg twice daily for 16 days and 
placebo twice daily for 16 days.
Results showed no statistically significant differences 
between asenapine and quetiapine and no reports of QTc 
interval 500 ms in any patient in any group. In addition, there 
were no reports of QTc increase from baseline 60 ms with 
asenapine, although there was 1 with quetiapine 375 mg twice 
daily and 2 with placebo. Furthermore, exposure-response 
modeling depicted a small positive relationship between 
QTc and plasma levels of both asenapine and quetiapine. In 
summary, although doses of asenapine 30 mg and 40 mg a 
day (but not 10 mg) showed a significant QTc prolongation 
compared with placebo, this was comparable to the increase 
seen with quetiapine.56
The effects of asenapine on cognitive function were 
assessed in a 6-week randomized, double-blind placebo- 
and risperidone-controlled study of 180 patients with acute 
exacerbation of schizophrenia.57 Patients were assigned 
to fixed doses of asenapine 5 mg twice daily, risperi-
done 3 mg twice daily or placebo. Patients treated with 
asenapine demonstrated improvement on all cognitive 
tests related to verbal learning and memory which are 
important domains of cognitive function in schizophrenia. 
Overall, the effects size compared with placebo on most 
cognitive function measures, was greater with asenapine 
than with risperidone, although the authors concluded that 
further investigations were needed in order to confirm 
these results.57
Efficacy and safety studies  
in bipolar disorder
The efficacy of asenapine in bipolar I disorder was evaluated 
in two 3-week multinational, randomized, double-blind, 
placebo- and olanzapine-controlled trials in patients with 
manic or mixed episodes associated with bipolar I disorder.58 
A total of 976 patients was randomly assigned in a 2:2:1 
ratio to flexible-dosing of asenapine 10 mg twice daily 
(adjustable to 5 mg twice daily), olanzapine 15 mg daily 
(adjustable to 5 to 20 mg daily) or placebo treatment. Results 
from these 2 studies found that the lean squares (LS) mean 
change in Young Mania Rating Scale (YMRS)59 score from 
baseline to day 21 were significantly greater (all P  0.05) 
with asenapine (-14.2 and -13.1) and olanzapine (-16.1 
and –13.9) than placebo (-10.8 and -7.4) in the 2 studies 
respectively. The active agents demonstrated superiority as 
early as day 2 of treatment.58
Asenapine was well tolerated in both studies and caused 
low incidence of weight gain. In the all-treated popula-
tion, the incidence of clinically significant weight gain was 
reported as 7% and 6% for asenapine, 19% and 13% for 
olanzapine and 1.2% and 0% for placebo in the 2 studies 
respectively.58
Following these 2 trials, a subsequent 9-week double-blind 
extension study60 was carried out comprising patients who 
had completed the initial 3-week phase. In addition, those 
who completed the 9-week extension period were also 
screened for an additional 40-week extension, focusing 
on safety of asenapine, thus bestowing a total treatment 
period of 1 year. Flexible doses of asenapine 5 to 10 mg 
twice daily or olanzapine 5 to 10 mg daily were initiated at 
the maintenance dosages used in the initial 3-week phase. 
The efficacy of asenapine was assessed using the mean 
change from baseline in YMRS total score which was –24.4 
with asenapine vs –23.9 with olanzapine. Inferential analysis 
indicated that asenapine was not inferior to olanzapine 
(P  0.0001). This comparable efficacy was maintained 
throughout the 40 week extension phase. In addition, more 
than 90% of patients showed response (YMRS total score 
reduced by 50%) or remission (total score 12) in both 
groups, and rates for completion and discontinuation were 
similar between the groups.60Neuropsychiatric Disease and Treatment 2009:5 488
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In terms of safety, incidence rates of treatment-related 
adverse events were 65.7% for asenapine and 61.7% for 
olanzapine. Although prolactin elevation, weight gain and 
metabolic syndrome were more common in the olanzapine 
group, EPS were more common with asenapine.60
For a comparison of asenapine’s adverse effects with 
other antipsychotics, see Table 1.
Conclusions and place in therapy
Whilst there are a variety of antipsychotics currently available 
on the market, there are clearly still certain needs in the treat-
ment of schizophrenia and bipolar disorder that have not yet 
been met. Available antipsychotics have shown to be effective 
against the positive symptoms of schizophrenia however they 
do little to alleviate the negative symptoms and the cognitive 
impairment often associated with the illness.
In addition, many of the available typical antipsychotics 
can cause movement disorders and atypical antipsychotics 
can cause considerable weight gain and serious metabolic 
abnormalities including diabetes. Hence, a drug that can 
potentially provide improvement in negative and cognitive 
symptoms as well as the positive symptoms of schizophrenia 
and which is metabolically neutral and has low rate of EPS 
is clearly warranted. Aripiprazole already meets some of 
these criteria; however, an alternative would be helpful.
Furthermore, the pharmaceutical industry has spent 
many years trying to develop a new drug that mimics the 
effectiveness of clozapine but with a much improved toxicity 
profile. A safer alternative to clozapine is also clearly needed, 
although for over 50 years now no drug has been shown to 
match its efficacy.
Asenapine has a high affinity for a number of receptors 
including antagonism at serotonergic, dopaminergic 
and adrenergic receptors but, unlike clozapine, it has no 
discernible affinity for muscarinic receptors. Studies showed 
that asenapine caused a significant reduction in PANSS 
positive and negative scores compared with placebo. Thus it 
may not only be effective in treating positive symptoms but 
also has a statistically significant advantage over placebo in 
treating negative symptoms, although the later may not be 
clinically significant. Further evidence is required in order 
to determine whether asenapine has advantages over placebo 
or other antipsychotics in terms of improving functional 
impairment. In bipolar disorder, asenapine showed com-
parable efficacy with olanzapine (which was maintained 
throughout a 40-week period), in patients with manic, mixed 
episodes or bipolar I disorder.
Asenapine appears to be well tolerated and has minimal 
effects on prolactin and metabolic parameters. Cardiovascular 
assessments found no cause for concern and asenapine’s 
effects on QTc prolongation were comparable to quetiapine, 
at the higher dose range of asenapine. The incidence of EPS 
was higher with asenapine than olanzapine in one study.
Overall, asenapine appears to have advantages over other 
antipsychotics for negative symptoms of schizophrenia 
and possibly cognitive function, although further research 
is required in order to assess whether this is of clinical 
importance and could improve the functional ability of 
patients. It may have a place in therapy as an atypical 
antipsychotic with neutral metabolic effects. There is no 
evidence as yet to show that it may be useful in treatment-
resistant schizophrenia, as an alternative to clozapine.
Table 1 Adverse effects of asenapine compared with other antipsychotics





Amisulpride + - + + + - +++
Aripiprazole - - +/- - + - -
Asenapine + + +/- - + - +/-
Chlorpromazine ++ +++ ++ ++ ++ ++ ++
Clozapine + +++ +++ +++ - +++ -
Haloperidol + + + + +++ - +++
Olanzapine + ++ +++ +++ +/- + +
Quetiapine ++ ++ ++ ++ - - -
risperidone + + ++ ++ + + +++
Sulpiride + - + + + - +++
Ziprasidone ++ + +/- - +/- - +/-
Abbreviations: +++, high incidence/severity; ++, moderate incidence/severity; +, low incidence/severity; –, very low incidence/severity.   Adapted from The Maudsley Prescribing 
Guidelines 10th Edition.61Neuropsychiatric Disease and Treatment 2009:5 489
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